Aerovate Therapeutics Stock (NASDAQ:AVTE)

Forecast Ownership Financials Chart

Previous Close

$2.68

52W Range

$2.63 - $884.98

50D Avg

$88.74

200D Avg

$82.18

Market Cap

$77.68M

Avg Vol (3M)

$7.64K

Beta

0.95

Div Yield

- (2.60%)

AVTE Company Profile

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jun 30, 2021

Website

AVTE Performance

AVTE Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-74.60M	$-81.41M	$-53.24M
Net Income	$-69.63M	$-75.52M	$-51.51M
EBITDA	$-74.31M	$-81.31M	$-53.17M
Basic EPS	$-2.44	$-2.87	$-2.10
Diluted EPS	$-2.44	$-2.87	$-2.10

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
MLYS	Mineralys Therapeutics, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
ADAG	Adagene Inc.
OPT	Opthea Limited
RZLT	Rezolute, Inc.
ACRV	Acrivon Therapeutics, Inc. Common Stock
ANTX	AN2 Therapeutics, Inc.